Ekso Bionics Holdings, Inc. (EKSO)
After hours:
| Previous close | 1.2800 |
| Open | 1.2700 |
| Bid | 1.2100 x 100 |
| Ask | 1.3000 x 100 |
| Day's range | 1.1701 - 1.2900 |
| 52-week range | 0.6200 - 3.1290 |
| Volume | |
| Avg. volume | 165,949 |
| Market cap | 22.379M |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
SAN RAFAEL, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2024 after the close of trading on Monday, April 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webca
- GlobeNewswire
Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal
SAN RAFAEL, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding (“PDAC”) contractor for the Centers for Medicare & Medicaid Services (“CMS”) has determined a final payment level of $91,031.93 for Medicare reimbursement of the Ekso Indego Personal, which took effect on April 1, 2024. As previou
- GlobeNewswire
Ekso Bionics Reports Record Annual Revenue of $18.3 Million
Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023. Recent Highlights and Accomplishments Achieved record revenue of $18.3 million for the 2023 full year, an increase of 42% year-over-yearSold a total of 151 EksoHeal
